Posted innews OB/GYN & Women’s Health Oncology
Harnessing HRD Testing and MYC Amplification to Optimize PARP Inhibitor Use in BRCA Wild-Type High-Grade Serous Ovarian Carcinoma
This article reviews real-world data supporting homologous recombination deficiency (HRD) testing in BRCA1/2 wild-type high-grade serous carcinoma and examines MYC amplification as a promising surrogate biomarker to guide PARP inhibitor therapy.